


**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1 - 7 (canceled).

8. (currently amended) A dosage form comprising a compound of formula 1:



**1**

or a pharmaceutically acceptable salt thereof, in an amount of from ~~0.5 to 30~~ 1 to 20 mg.

9-11 (canceled).

12. (original) The dosage form of claim 8, wherein the amount is from 2 to 10 mg.

13. (currently amended) The dosage form of claim 8, wherein the amount is ~~from 2.5 to 8~~ 5 mg.


14. (canceled).

15. (original) The dosage form of claim 8, wherein the dosage form is an oral dosage form.

16. (original) The dosage form of claim 8, wherein the dosage form is a tablet or capsule.

17- 31 (canceled).

32. (currently amended) A method of treating ~~VEGF-, PDGF- or c-Kit-~~ related cancer in a mammal, wherein the cancer is selected from lung cancer, pancreatic cancer, skin cancer, breast cancer, cancer of the thyroid gland, cancer of the parathyroid gland, renal cell carcinoma, and combinations thereof; the method comprising administering to the mammal a compound of formula 1:



**1**

or a pharmaceutically acceptable salt thereof, in an amount of from 0.5 to 30 1 to 20 mg per dose.

33-35. (canceled).

36. (original) The method of claim 32, wherein the amount is from 2 to 10 mg.

37. (currently amended) The method of claim 32, wherein the amount is ~~from 2.5 to 8~~ 5 mg.

38. (canceled).

39. (original) The method of claim 32, wherein the compound is administered orally.

40. (original) The method of claim 32, wherein the compound is administered at a dosage frequency of at least once per day.

41. (currently amended) The method of claim 32 36, wherein the compound is administered at a dosage frequency of at least twice per day.

42-48 (canceled).

49. (currently amended) The method of claim 46 32 wherein the cancer is cancer of the thyroid gland or cancer of the parathyroid gland, and wherein the compound is administered in an amount of from 1 mg to 20 10 mg per dose at a dosage frequency of twice per day.

50. (currently amended) The method of claim 46 32, wherein the cancer is breast cancer, and wherein the compound is administered in an amount of from 1 mg to 20 10 mg per dose at a dosage frequency of twice per day and wherein the method further comprises co-administering docetaxel.

Attorney Docket No. PC25581A  
Application No. 10/816,242  
Conf. No. 9207

51. (currently amended) The method of claim 46 32, wherein the cancer is pancreatic cancer, and wherein the compound is administered in an amount of from 1 mg to ~~20~~ 10 mg per dose at a dosage frequency of twice per day and wherein the method further comprises co-administering gemcitabine.

52. (New) The method of claim 32, wherein the cancer is renal cell carcinoma, and wherein the compound is administered in an amount of from 1 mg to 10 mg per dose at a dosage frequency of twice per day.

53. (New) The method of claim 32, wherein said lung cancer is non small cell lung cancer, and wherein the compound is administered in an amount of from 1 mg to 10 mg per dose at a dosage frequency of twice per day.